enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Analysts

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been assigned an average recommendation of “Buy” from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $29.78.

Several equities research analysts have commented on the stock. HC Wainwright assumed coverage on shares of enGene in a research note on Monday, December 23rd. They issued a “buy” rating and a $25.00 price target on the stock. Raymond James began coverage on shares of enGene in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 price target on the stock. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a report on Monday, December 23rd.

enGene Price Performance

ENGN opened at $7.16 on Friday. The company’s 50-day moving average price is $7.37 and its 200 day moving average price is $7.54. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $18.40. The firm has a market cap of $316.62 million, a price-to-earnings ratio of -12.34 and a beta of -0.65. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.06. As a group, sell-side analysts expect that enGene will post -1.57 earnings per share for the current year.

Institutional Trading of enGene

A number of large investors have recently added to or reduced their stakes in ENGN. Wolverine Asset Management LLC bought a new stake in enGene during the third quarter worth approximately $37,000. Point72 Asset Management L.P. lifted its position in shares of enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after acquiring an additional 619,100 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after acquiring an additional 389,918 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.